Imidazopyridyl compounds as aldosterone synthase inhibitors

The compound as defined in claim 1 or a pharmaceutically acceptable salt thereof, which has the structural Formula II

The compound as defined in claim 1 or a pharmaceutically acceptable salt thereof, which has the structural formula

The compound as defined in claim 1 or a pharmaceutically acceptable salt thereof, which has the structural formula

The compound as defined in claim 1 or a pharmaceutically acceptable salt thereof, which has the structural formula

The compound as defined in claim 1 which isn6-methyl-2-(6-methylpyridin-3-yl)-3-methylimidazo[1,2-a]pyridine;8-methyl-2-(6-methylpyridin-3-yl)-3-methylimidazo[1,2-a]pyridine;4-(6-fluoro-3-ethylimidazo[1,2-a]pyridin-2-yl)isoquinoline;6-fluoro-3-methyl-2-(5-methoxypyridin-3-yl)imidazo[1,2-a]pyridine;6-fluoro-3-methyl-2-(5-methylpyridin-3-yl)imidazo[1,2-a]pyridine;7-fluoro-2-(5-fluoropyridin-3-yl)-3-methylimidazo[1,2-a]pyridine;6-fluoro-3-methyl-2-(4-methylpyridin-3-yl)imidazo[1,2-a]pyridine;7-methyl-2-(6-methylpyridin-3-yl)-3-methylimidazo[1,2-a]pyridine;3-cyclopropyl-6-fluoro-2-(5-methylpyridin-3-yl)imidazo[1,2-a]pyridine;3-cyclopropyl-6-fluoro-2-(6-methylpyridin-3-yl)imidazo[1,2-a]pyridine;2-(5-(3-cyclopropyl-6-fluoroimidazo[1,2-a]pyridin-2-yl)pyridin-3-yl)-1,1,1-trifluoropropan-2-ol;3-cyclopropyl-6-fluoro-2-(5-methoxypyridin-3-yl)imidazo[1,2-a]pyridine;3-cyclopropyl-6-fluoro-2-(5-(trifluoromethyl)pyridin-3-yl)imidazo[1,2-a]pyridine;4-(3-cyclopropyl-6-fluoroimidazo[1,2-a]pyridin-2-yl)isoquinoline;3-cyclopropyl-6-fluoro-2-(pyridin-3-yl)imidazo[1,2-a]pyridine;N-((5-(3-cyclopropyl-6-fluoroimidazo[1,2-a]pyridin-2-yl)pyridin-3-yl)methyl) ethanesulfonamide;3-cyclopropyl-6-fluoro-2-(5-fluoropyridin-3-yl)imidazo[1,2-a]pyridine;4-(3-cyclopropyl-8-fluoroimidazo[1,2-a]pyridin-2-yl)isoquinoline;6-fluoro-2-(4-methylpyridin-3-yl)imidazo[1,2-a]pyridine;6-fluoro-2-(5-methylpyridin-3-yl)imidazo[1,2-a]pyridine;or a pharmaceutically acceptable salt thereof.

A pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Formula I as defined in claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

A pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Formula I as defined in claim 1 or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of at least one additional therapeutic agent and a pharmaceutically acceptable carrier.

A method for the treatment of one or more conditions associated with inhibiting CYP11B2, wherein said conditions are selected from hypertension, heart failure, congestive heart failure, diastolic dysfunction, left ventricular diastolic dysfunction, heart failure, diastolic dysfunction, left ventricular diastolic dysfunction, diastolic heart failure, systolic dysfunction, hypokalemia, renal failure, restenosis, syndrome X, nephropathy, post-myocardial infarction, coronary heart diseases, increased formation of collagen, fibrosis and remodeling following hypertension and endothelial, which comprises administering a therapeutically effective amount at least one compound of Formula I as defined in claim 1 or a pharmaceutically acceptable salt thereof to a mammal in need of such treatment.